Navigation Links
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
Date:5/27/2009

and nervous systems. While these NET are often slow-growing, when the tumor is inoperable patients with advanced NET have limited treatment options(2).

The safety findings observed in the PROMID study were consistent with those seen in previous studies of Sandostatin LAR in patients with NET. The most frequently observed serious adverse events affected the gastrointestinal tract, hematopoietic system and other general symptoms such as fatigue and fever(1).

Afinitor in patients with advanced liver cancer

Phase I data (abstract #4587) demonstrated that 61% of patients with advanced hepatocellular carcinoma (HCC) who received daily treatment with Afinitor(R) (everolimus) tablets had tumors that stabilized or reduced in size(3).

There are currently a limited number of treatment options for patients with advanced HCC, the stage when most are diagnosed(4)(5). Everolimus shows potential to help address this unmet medical need(3).

The trial, conducted in Taiwan by Dr Li-Tzong Chen from the National Health Research Institute, included 36 advanced HCC patients who progressed after various systemic therapies or who were no longer candidates for local therapies, including surgery, percutaneous ablation or transcatheter arterial chemoembolization. Of the 31 patients evaluable in the trial, 16 received everolimus (known as RAD001 in this study) daily. The study objective was to define the maximum tolerated dose and pharmacokinetics of everolimus(3).

The Grade 3 and 4 adverse events reported in the study included elevated bilirubin, drop in platelets count, diarrhea, bleeding, cardiac ischemia, elevated liver function tests and infection. Reactivation of Hepatitis B virus was observed in four patients as well as reactivation of Hepatitis C virus in one patient(3).

Based on these data, a global Phase III clinical trial to study the daily everolimus regimen in patien
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
2. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
3. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
4. Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
5. Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
6. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
7. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
8. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
9. Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Dont Get Their Families Vaccinated
10. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
11. Video: Answer to Curing a Failing Heart May Exist in Bodys Own Do-It-Yourself Repair Kit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
(Date:7/14/2014)... The Encino cosmetic dentist ... Lumineers and porcelain veneers. These restorations are an ... preparation and greater loss of healthy tooth tissue. They ... visible flaws on the tooth. Encino dentist Dr. Mastour ... to ensure they offer the most appropriate treatment recommendations ...
(Date:7/14/2014)... 14, 2014 (HealthDay News) -- Being physically active in ... Alzheimer,s disease and other types of dementia, suggest the ... we found that physical exercise at various levels, especially ... Geda from the Mayo Clinic, said in an Alzheimer,s ... they are not yet conclusive. More research is needed ...
(Date:7/14/2014)... July 14, 2014 ... performance liquid chromatography or UPLC is a ... liquid chromatography that involves the use of ... to separate chromatographic compounds. This highly sensitive ... detection and analysis of chromatography samples. UPLC ...
(Date:7/14/2014)... Huntington Beach, CA (PRWEB) July 14, 2014 ... of thousands of people undergo plastic surgery to reduce ... hit the market, however, eliminates the need to go ... mouth guard that works the jaw muscles, therefore tightening ... of having two chins. , Jawflex is used for ...
(Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Staying Active May Help Prevent Dementia 2Health News:Need for Faster Sample Analysis Drives Demand for UPLC, According to New Trend Report Published by Global Industry Analysts, Inc. 2Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3
... Speakers ... Exposition (ACE10), June 20-24, in Chicago, Illinois. , ... Denver (Vocus) February 25, 2010 -- Speakers have been ... June 20-24, in Chicago, Illinois. , ,Denis Hayes will be the highlighted speaker at ...
... , ... Examines IT Executive,s Opinions on Outsourcing , ... Westborough, MA (PRWEB) February 25, 2010 -- Advans, a ... that highlight the growing popularity of domestic outsourcing. According to the Advans’ IT Outsourcing ...
... ... New Inguinal Hernia Product Range Freedom-I, with an Aim to Improve Surgical Outcomes and Take ... ... focused on bringing innovations to the field of medical devices. For the past four years ...
... ... for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, is pleased to announce a ... of OA progression. , ... Rosemont, IL (Vocus) February 25, 2010 -- The American Orthopaedic Society for ...
... ... feel like they are falling apart at home, psychotherapeutic interventions provide families with a growing ... (PRWEB) ... like they are falling apart at home, psychotherapeutic interventions provide families with a growing array ...
... ... continue to await their orders of Xyngular Xyng™ as Zija,s NEW! ... Xyngular™ to market months before their NEW! Xyng™ product was released ... People from all over the world are calling to become distributors ...
Cached Medicine News:Health News:AWWA Announces ACE10 Speakers 2Health News:Advans Survey Reveals that 75 Percent of Executives Prefer Domestic Outsourcing vs. Offshore 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 2Health News:Insightra Medical Inc Gains CE Mark on the Freedom(TM) Inguinal Hernia Product Range 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:New Approaches to Teen Therapy Bring Results 2Health News:New Approaches to Teen Therapy Bring Results 3Health News:New Approaches to Teen Therapy Bring Results 4Health News:New Approaches to Teen Therapy Bring Results 5Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 2Health News:Xyngular™ Distributors Continue Waiting For Xyngular Xyng™ As Zija's XM3™ "Happy Pill" Reaches Record Sales 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: